<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12476280</article-id><article-id pub-id-type="pmcid-ver">PMC12476280.1</article-id><article-id pub-id-type="pmcaid">12476280</article-id><article-id pub-id-type="pmcaiid">12476280</article-id><article-id pub-id-type="doi">10.7759/cureus.91169</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pain Management</subject></subj-group><subj-group><subject>Rheumatology</subject></subj-group></article-categories><title-group><article-title>Inflammatory Findings on Musculoskeletal Ultrasound Do Not Affect Pain Intensity but May Influence Pain Quality in Patients with Refractory Arthralgia: A Cross-Sectional Study Using PainDETECT and Musculoskeletal Ultrasound</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Harada</surname><given-names initials="M">Mariko</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ogasawara</surname><given-names initials="M">Michihiro</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nojiri</surname><given-names initials="S">Shuko</given-names></name><xref rid="aff-2" ref-type="aff">2</xref><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Matsuki-Muramoto</surname><given-names initials="Y">Yuko</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kawamoto</surname><given-names initials="T">Toshio</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamaji</surname><given-names initials="K">Ken</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tamura</surname><given-names initials="N">Naoto</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, JPN </aff><aff id="aff-2">
<label>2</label>
Medical Technology Innovation Center, Juntendo University, Tokyo, JPN </aff><aff id="aff-3">
<label>3</label>
Clinical Research and Trial Center, Juntendo University, Tokyo, JPN </aff><author-notes><corresp id="cor1">
Mariko Harada <email>ma-noda@juntendo.ac.jp</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>8</month><year>2025</year></pub-date><volume>17</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">494304</issue-id><elocation-id>e91169</elocation-id><history><date date-type="accepted"><day>28</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 22:25:34.597"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025, Harada et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Harada et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cureus-0017-00000091169.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cureus.com/articles/381310-inflammatory-findings-on-musculoskeletal-ultrasound-do-not-affect-pain-intensity-but-may-influence-pain-quality-in-patients-with-refractory-arthralgia-a-cross-sectional-study-using-paindetect-and-musculoskeletal-ultrasound">This article is available from https://cureus.com/articles/381310-inflammatory-findings-on-musculoskeletal-ultrasound-do-not-affect-pain-intensity-but-may-influence-pain-quality-in-patients-with-refractory-arthralgia-a-cross-sectional-study-using-paindetect-and-musculoskeletal-ultrasound</self-uri><abstract><p>Aim: The aim of this study was to investigate the prevalence and associated factors of neuropathic pain (NeP) in patients with refractory arthralgia and to evaluate the role of musculoskeletal ultrasound (MSKUS) in its assessment.</p><p>Materials and methods: A cross-sectional study was conducted in 187 patients with refractory arthralgia who underwent MSKUS to assess inflammation and NeP using the PainDETECT Questionnaire (PDQ). Clinical data, including demographics, disease activity, and functional status, were collected.&#160;The associations between NeP and clinical indicators, as well as MSKUS findings, were analyzed.</p><p>Results: A total of 187 patients were enrolled, of whom 41 (21.9%) were diagnosed with NeP. The strongest associated factors of pain in the overall cohort were PDQ score (p&lt;0.001) and patient global assessment (PGA) (p&lt;0.001).&#160;No significant correlation was found between pain and inflammatory findings on MSKUS. For the prediction of NeP, the numeric rating scale (NRS) score was the only significant associated factor (p&lt;0.001, odds ratio (OR)=1.37, 95% confidence interval (CI): 1.17-1.60), whereas inflammation detected on MSKUS was not associated with NeP (p=0.19, OR=0.80, 95% CI: 0.57-1.12). Analysis of the PDQ components showed that burning pain severity was significantly higher in the moderate/high (M/H) inflammation group compared to the none/low (N/L) inflammation group (Mann-Whitney U test, p=0.032; logistic regression analysis, p=0.01, OR=1.53, 95% CI: 1.1-2.1).</p><p>Correlations between NRS and NeP were significant in both the N/L (Spearman's &#961;=0.516, p&lt;0.001; R&#178;=0.2717, p&lt;0.001) and M/H (Spearman's &#961;=0.397, p&lt;0.001; R&#178;=0.1534, p&lt;0.001) groups for all patients. However, within the rheumatoid arthritis (RA) subgroup, a significant correlation between NRS and NeP was observed only in the M/H group (Spearman's &#961;=0.431, p=0.002; R&#178;=0.212, p&lt;0.001) but not in the N/L group (Spearman's &#961;=0.251, p=0.3; R&#178;=0.03849, p=0.4208).</p><p>Conclusion: NeP was most strongly associated with NRS and MSKUS. Inflammation may change the quality of pain rather than the intensity.</p></abstract><kwd-group kwd-group-type="author"><kwd>diagnostic musculoskeletal ultrasound</kwd><kwd>neuropathic pain</kwd><kwd>paindetect questionnaire</kwd><kwd>refractory pain</kwd><kwd>rheumatoid arthriitis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by synovitis and severe joint pain. Advances in RA management have allowed 50% to 64% of patients to live in remission or with low disease activity [<xref rid="REF1" ref-type="bibr">1</xref>]. However, pain often persists despite proper treatment of inflammation based on the treat-to-target (T2T) strategy [<xref rid="REF2" ref-type="bibr">2</xref>], and pain may increase over time after several years of treatment [<xref rid="REF3" ref-type="bibr">3</xref>]. Non-inflammatory pain, such as neuropathic pain (NeP) and chronic widespread pain (CWP), has been identified as a cause of this persistent pain, in addition to nociceptive pain caused by synovitis [<xref rid="REF2" ref-type="bibr">2</xref>,<xref rid="REF4" ref-type="bibr">4</xref>,<xref rid="REF5" ref-type="bibr">5</xref>]. In several studies of patients whose RA status ranged from remission to high disease activity, NeP was present in 14% to 40% of individuals [<xref rid="REF4" ref-type="bibr">4</xref>,<xref rid="REF6" ref-type="bibr">6</xref>-<xref rid="REF12" ref-type="bibr">12</xref>], a percentage that was three times as high as that in the general population [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>NeP is defined as &#8220;pain caused by a lesion or disease of the somatosensory system [<xref rid="REF13" ref-type="bibr">13</xref>].&#8221; Patients with RA are known to have NeP-like pain, although there is often no peripheral or central nervous system lesion or disease. The following mechanism is supposed to be responsible: persistent pain or inflammation causes activation of joint nociceptors, peripheral sensitisation, and changes in central pain processing, resulting in increased central pain sensitisation and loss of descending analgesic mechanisms [<xref rid="REF14" ref-type="bibr">14</xref>]. Although the mechanism is different, these RA symptoms are similar to those in NeP, including, for instance, burning pain and allodynia, and have been treated as NeP in many previous studies [<xref rid="REF7" ref-type="bibr">7</xref>, <xref rid="REF9" ref-type="bibr">9</xref>, <xref rid="REF11" ref-type="bibr">11</xref>, <xref rid="REF14" ref-type="bibr">14</xref>, <xref rid="REF15" ref-type="bibr">15</xref>]. However, in this study, we will be discussing NeP, which has been the subject of many previous studies in relation to RA. NeP in RA contributes to physical dysfunction and decreased quality of life [<xref rid="REF7" ref-type="bibr">7</xref>], so an early diagnosis and proper treatment are important. Non-inflammatory pain such as NeP is also a problem in systemic sclerosis (SSc), osteoarthritis (OA) [<xref rid="REF16" ref-type="bibr">16</xref>], psoriatic arthritis (PsA), and Sjogren syndrome (SjS). Despite questionnaires used to identify NeP, such as the PainDETECT questionnaire (PDQ) [<xref rid="REF17" ref-type="bibr">17</xref>], it may be challenging in daily medical practice to differentiate NeP from nociceptive pain solely based on clinical examination and blood tests.</p><p>NeP in RA is usually associated with patient-reported outcomes (PROs), especially those related to pain and psychiatric symptoms. Examples include health-related quality of life [<xref rid="REF16" ref-type="bibr">16</xref>], visual analogue scale for pain (pain VAS), tender joint count (TJC) [<xref rid="REF4" ref-type="bibr">4</xref>, <xref rid="REF9" ref-type="bibr">9</xref>], 36-item short form (SF36) mental component summary [<xref rid="REF9" ref-type="bibr">9</xref>, <xref rid="REF10" ref-type="bibr">10</xref>], and SF36 physical component summary [<xref rid="REF10" ref-type="bibr">10</xref>]. Body mass index (BMI) &#8805;22 kg/m<sup>2</sup> and non-clinical remission [<xref rid="REF14" ref-type="bibr">14</xref>] are also relevant. For non-RA, other factors have been reported, including the following: the Mean Modified Rodnan Skin Score [<xref rid="REF18" ref-type="bibr">18</xref>] and the modified Medsger Severity Scale for muscle lesions in SSc; pain severity in OA [<xref rid="REF16" ref-type="bibr">16</xref>]; small fibre neuropathy in SjS; and the swollen joint count (SJC), dactylitis, and fatigue in PsA. While blood test data indicating inflammation, such as C-reactive protein (CRP), were not found to correlate with NeP [<xref rid="REF4" ref-type="bibr">4</xref>,<xref rid="REF14" ref-type="bibr">14</xref>], in some cases, inflammation-related factors such as non-clinical remission and the presence of dactylitis have been found to predict NeP. Thus, the association between inflammation and NeP is still controversial.</p><p>Because musculoskeletal ultrasound (MSKUS) is the most sensitive means of detecting joint inflammation, patients with long-term or unexplained joint pain often undergo MSKUS. Even in clinical remission, the prevalence of power Doppler (PD) positivity in MSKUS was 44%, and this finding predicted the risk of relapse and structural progression after one to two years [<xref rid="REF19" ref-type="bibr">19</xref>]. MSKUS can also detect early arthritis, and 89% of patients without joint inflammation were free of arthritis one year later [<xref rid="REF20" ref-type="bibr">20</xref>]. The European Alliance of Associations for Rheumatology (EULAR) recommendations also suggest that MSKUS should be used to determine the presence of inflammation in difficult-to-treat RA (D2TRA) [<xref rid="REF21" ref-type="bibr">21</xref>]; if MSKUS shows no joint inflammation, synovitis can be ruled out, and non-pharmacologic therapy is recommended. However, pain quality in patients who are PD negative has not been investigated.</p><p>For this reason, patients with refractory arthralgia visit the MSKUS outpatient department. The aim of this study was to explore the factors most strongly associated with pain and to investigate the prevalence and associated factors of NeP, and to examine the role of MSKUS in&#160;the assessment of NeP using MSKUS and the PDQ in this group of patients with refractory arthralgia visiting the MSKUS outpatient department.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Study design and population</p><p>This observational, cross-sectional study was conducted at the Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine in Tokyo, Japan. From August 2020 to June 2021, we recruited consecutive patients with refractory arthralgia who underwent MSKUS to evaluate inflammation and conducted the PDQ to evaluate the presence of NeP. Patients with known causes of neuropathy, for example, spinal canal stenosis, carpal tunnel syndrome, diabetic neuropathy, and cervical hernia, were excluded from the study. The ethics committee at Juntendo University approved this study (study no. H21-0021). All participants gave written informed consent according to the Declaration of Helsinki.</p><p>Variables and outcome measures</p><p>Clinical Data</p><p>The following patient data were collected from medical records: age, gender, diagnosis, disease duration, past history, medication history (prednisolone (PSL), methotrexate (MTX), biologic synthetic disease-modifying anti-rheumatic drugs (bDMARDs), targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-anxiety drugs), and blood tests (rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (ACPA), anti-SS-A antibody, CRP, and erythrocyte sedimentation rate (ESR)).</p><p>Disease Activity Evaluation</p><p>RA disease activity was evaluated by the disease activity score for 28 joints (DAS28)-ESR and DAS28-CRP. Together, these include SJC and TJC for 28 joints, as well as a patient global assessment (PGA) for general disease activity (0-10) based on questionnaire responses, and CRP and ESR levels. The NRS score was also evaluated using a questionnaire (0-10). In non-RA arthritis, disease activity was not evaluated.</p><p>Functional Evaluation</p><p>Functional disability was assessed by the Health Assessment Questionnaire Disability Index (HAQ). On a questionnaire comprising items rated on a four-point scale, patients indicated how difficult it was to perform 20 daily activities.</p><p>PDQ</p><p>We evaluated NeP using the Japanese version of the PDQ [<xref rid="REF22" ref-type="bibr">22</xref>]. Although the definition of neuropathic pain in the narrow sense requires pain and sensory abnormalities consistent with the site of innervation, the accuracy of the PDQ as a screening tool is well accepted. The PDQ has a sensitivity of 85% and a specificity of 80% in differentiating nociceptive pain from NeP [<xref rid="REF23" ref-type="bibr">23</xref>]. It was also indicated to be useful for the evaluation of NeP in RA [<xref rid="REF11" ref-type="bibr">11</xref>], OA, fibromyalgia, and diverse musculoskeletal conditions [<xref rid="REF23" ref-type="bibr">23</xref>]. The PDQ score consists of the pattern of pain over the course of the disease, the presence of radiating pain, gradation of pain, and quality of pain (burning, tingling or prickling, allodynia, sudden pain attack, hypersensitivity to cold or heat, numbness, or hypersensitivity to pressure). The total score ranges from 0 to 38 points. Scores &#8804;12 indicate unlikely NeP, scores &#8805;19 indicate likely NeP, and values from 13 to 18 indicate possible NeP. Based on the above, we classified patients with a score &#8804;12 as the non-NeP group and those with a score &#8805;13 as the NeP group [<xref rid="REF4" ref-type="bibr">4</xref>,<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF10" ref-type="bibr">10</xref>,<xref rid="REF11" ref-type="bibr">11</xref>,<xref rid="REF14" ref-type="bibr">14</xref>].&#160;Additionally, this questionnaire simultaneously assessed the intensity of pain, including the current NRS, the severity of the most intense pain experienced in the past, and the average pain level over the past four weeks.</p><p>Radiographic Damage</p><p>X-rays of the hand or wrist taken within one year from the date of MSKUS were categorised using the Steinbrocker classification into four stages by a single examiner who was blind to patient clinical data, diagnosis, and medication.</p><p>MSKUS</p><p>MSKUS was performed using an ARIETTA 70 US unit (Fujifilm Healthcare Corporation, Tokyo, Japan) equipped with a high-frequency linear transducer L64 (5-18 MHz). MSKUS was performed by three rheumatologist sonographers (MO, TK, and YM), each with more than five years of experience in MSKUS (more than 2,500 cases) and blind to patient diagnosis, clinical data, and radiographic data.</p><p>We conducted MSKUS examination of all painful joints and examined the wrist, interphalangeal (IP) joint, proximal interphalangeal (PIP) joint, and metacarpophalangeal (MCP) joint bilaterally. Longitudinal and transverse scans were performed using both B-mode and Doppler mode. Synovial thickening and effusion were defined as hypoechoic areas of the joint, tendon, and bursa and were semiquantitatively graded using the four-point Grey Scale, with scores ranging from 0 to three. PD signals were used to display flow signals in the synovium and were semiquantitatively graded using the four-point PD scale, with scores ranging from 0 to three [<xref rid="REF24" ref-type="bibr">24</xref>]. For all test results, the maximum grade was taken as the total MSKUS score of the patient, which was classified into four levels: no, low, moderate, or high.</p><p>All grade decisions were made by MO, who has completed the EULAR Sonography course (Advanced Musculoskeletal Ultrasound in Rheumatology and Course for Ultrasound Trainers in Rheumatology: Teach the Teachers). Factors that can influence US findings, such as NSAID use, room temperature, and body position, were considered.</p><p>Statistical methods</p><p>To assess the contributing factors to pain, multiple regression analysis was used to examine patient background, blood and imaging test results, and medication history for the whole patient group and for the group of RA patients. And, to determine the associated factors of NeP, we compared the NeP and non-NeP groups. Data were presented as mean (SD) for continuous variables and as frequencies for categorical variables. Univariate analysis was performed using Fisher&#8217;s exact test for normally distributed variables and the Mann-Whitney U (MWU) test for non-normally distributed variables. Multivariate analysis was performed using logistic regression, and an age-adjusted model was created that included US findings of interest and items that were significantly different (P&lt;0.05) in the univariate analysis. The multiple imputation analysis included all variables used in the final analysis with 10 imputations by using the multivariate imputation by chained equations (MICE) [<xref rid="REF25" ref-type="bibr">25</xref>] method, applying PMM to continuous variables (SS-A, CCP, RF, CRP, ESR) and POLR to categorical variables (XP stage) to produce imputed data. We confirmed that there was no significant difference between 10 and 100 iterations in the missing value imputation method. We conducted analyses with two settings, m=10 and m=100, and confirmed the consistency of the results. When comparing the imputation results for m=10 and m=100, all variables showed high consistency in terms of mean and median values.</p><p>To investigate the association of inflammation and quality of pain, patients were divided into 2 subgroups based on the presence of no/low US inflammation (N/L group) or moderate/high US inflammation (M/H group). The MWU test was performed on PDQ components between the N/L and M/H groups as a univariate analysis, followed by logistic regression analysis.</p><p>To further investigate the association between NeP and US-determined no/low inflammatory findings, divided into N/L and M/H groups, a subgroup analysis was then conducted. In each group, Spearman's rank correlation coefficient between NRS and NeP was determined, and single regression analyses were performed. Next, we conducted the same test focusing on the RA patient group to investigate the correlation between NeP and NRS scores. In addition, a comparison between the N/L group and the M/H group was performed using simple regression analysis in&#160;the RA group. Receiver operating characteristic (ROC) curve analysis was also conducted on the RA patient group to calculate the cut-off value of the NRS score that can diagnose NeP.</p><p>Statistical significance was defined as p&#8804;0.05. All analyses were performed with EZR (V.1.54; Saitama Medical Center, Jichi Medical University, Saitama, Japan) [<xref rid="REF26" ref-type="bibr">26</xref>] and SAS (V.9.4; SAS Inc., Cary, NC).</p></sec><sec sec-type="results"><title>Results</title><p>Patient characteristics</p><p>In total, 195 patients underwent MSKUS during the study period, and 187 were enrolled after eight were excluded because NeP apparently had causes other than arthralgia (carpal tunnel syndrome, three; spinal canal stenosis, two; cervical disc hernia, three) (Figure <xref rid="FIG1" ref-type="fig">1</xref>).</p><fig position="anchor" fig-type="figure" id="FIG1" orientation="portrait"><label>Figure 1</label><caption><title>Study flowchart</title><p>Patients with arthralgia who were examined by US at our department and interviewed with the PDQ to evaluate the presence of NeP were enrolled in this study from August 2020 to June 2021, excluding patients with diagnosed neuropathy.</p><p>PDQ: painDETECT questionnaire; NeP: neuropathic pain; US: ultrasound</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091169-i01.jpg"/></fig><p>Of the 187 patients, the median (range) age was 55 (16-83) years, and 148 (79.1%) patients were females. Seventy patients (37.4%) had RA, 80 (42.8%) had undiagnosed arthralgia, and the remaining 37 had other rheumatic diseases (SjS, eight; polymyalgia rheumatica, eight; PsA, five; mixed connective tissue disease, four; systemic lupus erythematosus, two; gout, two; remitting seronegative symmetrical synovitis with pitting edema, two; ulcerative colitis, one; SSc, one; familial Mediterranean fever, one; polymyositis, one; polyarteritis nodosa, one; Takayasu arteritis, one; antiphospholipid syndrome, one; SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome, one; and Beh&#231;et's disease, one). Forty-one patients (21.9%) had NeP (Table <xref rid="TAB1" ref-type="table">1</xref>).</p><p>Associated factors of pain</p><p>The strongest correlations with pain were PDQ score (p&lt;0.001) and PGA (p&lt;0.001) in the overall group, and in the RA group, the strongest correlations were PDQ score (p=0.04) and PGA (p&lt;0.001). There was no significant correlation in inflammatory findings on MSKUS with X-ray findings, blood test results, or medications.</p><p>Associated factors of NeP</p><p>The NeP group had a significantly higher NRS score (p&lt;0.001), PGA (p=0.005), TJC (p=0.001), SJC (p=0.001), and HAQ score (p=0.002) than the non-NeP group. There were no significant differences in inflammatory findings on MSKUS, X-ray findings, blood test results, or medications (Table <xref rid="TAB1" ref-type="table">1</xref>).</p><table-wrap position="float" id="TAB1" orientation="portrait"><label>Table 1</label><caption><title>Characteristics of patients with unlikely NeP versus likely and possible NeP</title><p>NeP: neuropathic pain; RA: rheumatoid arthritis; NRS: numerical rating scale score; Average: average pain in the last week; Greatest: greatest pain in the last week; PGA: patient global assessment; TJC: tender joint count; SJC: swollen joint count; HAQ: health assessment questionnaire; US: ultrasound; MTX: methotrexate; DMARD: disease-modifying anti-rheumatic drug; PSL: prednisolone; NSAID: non-steroidal anti-inflammatory drug; CRP: c-reactive protein; ESR: erythrocyte sedimentation rate; ACPA: anti-cyclic citrullinated peptide antibody; RF: rheumatoid factor; Other diagnoses: Gout, Sj&#246;gren's syndrome, psoriatic arthritis, polymyalgia rheumatica, systemic lupus erythematosus, RS3PE syndrome, systemic sclerosis, mixed connective tissue disease, ulcerative colitis, familial Mediterranean fever, dermatomyositis, Beh&#231;et's disease, SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome, Takayasu arteritis, osteoarthritis, anti-phospholipid antibody syndrome</p><p>*Fisher&#8217;s exact test; *Mann&#8211;Whitney U test</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Variable</td><td rowspan="1" colspan="1">Overall</td><td rowspan="1" colspan="1">Unlikely NeP</td><td rowspan="1" colspan="1">Likely and possible NeP</td><td rowspan="1" colspan="1">p-value</td></tr><tr><td rowspan="1" colspan="1">n</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">146</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Age (years) &#8211; median (min-max)</td><td rowspan="1" colspan="1">55 (16&#8211;83)</td><td rowspan="1" colspan="1">55 (16&#8211;83)</td><td rowspan="1" colspan="1">57 (17&#8211;78)</td><td rowspan="1" colspan="1">0.28**</td></tr><tr><td rowspan="1" colspan="1">Female sex &#8211; n (%)</td><td rowspan="1" colspan="1">148 (79)&#160;</td><td rowspan="1" colspan="1">114 (78)&#160;</td><td rowspan="1" colspan="1">34 (83)&#160;</td><td rowspan="1" colspan="1">0.66*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Diagnosis</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">RA, n (%)</td><td rowspan="1" colspan="1">&#160;70 (37)&#160;</td><td rowspan="1" colspan="1">&#160;58 (40)&#160;</td><td rowspan="1" colspan="1">12 (29)&#160;</td><td rowspan="1" colspan="1">0.5*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Not diagnosed, n (%)</td><td rowspan="1" colspan="1">&#160;80 (43)&#160;</td><td rowspan="1" colspan="1">&#160;60 (41)&#160;</td><td rowspan="1" colspan="1">20 (49)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Others, n (%)</td><td rowspan="1" colspan="1">&#160;37 (20)&#160;</td><td rowspan="1" colspan="1">&#160;28 (19)&#160;</td><td rowspan="1" colspan="1">&#160;9 (22)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Symptoms duration (years), median (min-max)</td><td rowspan="1" colspan="1">&#160;2 (0&#8211;33)</td><td rowspan="1" colspan="1">&#160;2 (0&#8211;33)</td><td rowspan="1" colspan="1">&#160;2 (0&#8211;22)</td><td rowspan="1" colspan="1">0.83**</td></tr><tr><td rowspan="1" colspan="1">NRS score, median (min-max)</td><td rowspan="1" colspan="1">&#160;4 (0&#8211;10)</td><td rowspan="1" colspan="1">&#160;4 (0&#8211;10)</td><td rowspan="1" colspan="1">&#160;7 (0&#8211;9)</td><td rowspan="1" colspan="1">&lt;0.001**</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Average, median (min-max)</td><td rowspan="1" colspan="1">&#160;5 (0&#8211;10)</td><td rowspan="1" colspan="1">&#160;4 (0&#8211;9)</td><td rowspan="1" colspan="1">&#160;7 (1&#8211;10)</td><td rowspan="1" colspan="1">&lt;0.001**</td></tr><tr><td rowspan="1" colspan="1">Greatest, median (min-max)</td><td rowspan="1" colspan="1">&#160;7 (0&#8211;10)</td><td rowspan="1" colspan="1">&#160;5 (0&#8211;10)</td><td rowspan="1" colspan="1">&#160;9 (4&#8211;10)</td><td rowspan="1" colspan="1">&lt;0.001**</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">PGA, median (min-max)</td><td rowspan="1" colspan="1">&#160;5 (0&#8211;10)</td><td rowspan="1" colspan="1">&#160;4 (0&#8211;10)</td><td rowspan="1" colspan="1">&#160;5 (0&#8211;10)</td><td rowspan="1" colspan="1">0.005**</td></tr><tr><td rowspan="1" colspan="1">TJC53, median (min-max)</td><td rowspan="1" colspan="1">&#160;6 (0&#8211;53)</td><td rowspan="1" colspan="1">&#160;5 (0&#8211;53)</td><td rowspan="1" colspan="1">11 (1&#8211;36)</td><td rowspan="1" colspan="1">0.001**</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">SJC, median (min-max)</td><td rowspan="1" colspan="1">&#160;1 (0&#8211;43)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;43)</td><td rowspan="1" colspan="1">&#160;3 (0&#8211;42)</td><td rowspan="1" colspan="1">0.001**</td></tr><tr><td rowspan="1" colspan="1">HAQ, median (min-max)</td><td rowspan="1" colspan="1">&#160;0.25 (0&#8211;2.8)</td><td rowspan="1" colspan="1">&#160;0.12 (0&#8211;2.8)</td><td rowspan="1" colspan="1">&#160;0.38 (0&#8211;2.5)</td><td rowspan="1" colspan="1">0.002**</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">US inflammation, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">0.88*</td></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">&#160;69 (37)&#160;</td><td rowspan="1" colspan="1">&#160;53 (36)&#160;</td><td rowspan="1" colspan="1">16 (39)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">&#160;32 (17)&#160;</td><td rowspan="1" colspan="1">&#160;24 (16)&#160;</td><td rowspan="1" colspan="1">&#160;8 (20)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Moderate</td><td rowspan="1" colspan="1">&#160;51 (27)&#160;</td><td rowspan="1" colspan="1">&#160;40 (27)&#160;</td><td rowspan="1" colspan="1">11 (27)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">&#160;35 (19)&#160;</td><td rowspan="1" colspan="1">&#160;29 (20)&#160;</td><td rowspan="1" colspan="1">&#160;6 (15)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">X-ray Steinblocker grade, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">137 (73)&#160;</td><td rowspan="1" colspan="1">103 (71)&#160;</td><td rowspan="1" colspan="1">34 (83)&#160;</td><td rowspan="1" colspan="1">0.29*</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">&#160;29 (16)&#160;</td><td rowspan="1" colspan="1">&#160;26 (18)&#160;</td><td rowspan="1" colspan="1">&#160;3 (7)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">&#160;14 (8)&#160;</td><td rowspan="1" colspan="1">&#160;12 (8)&#160;</td><td rowspan="1" colspan="1">&#160;2 (5)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">&#160; 7 (4)&#160;</td><td rowspan="1" colspan="1">&#160; 5 (3)&#160;</td><td rowspan="1" colspan="1">&#160;2 (5)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Mental disorder, n (%)</td><td rowspan="1" colspan="1">&#160;18 (10)&#160;</td><td rowspan="1" colspan="1">&#160;12 (8)&#160;</td><td rowspan="1" colspan="1">&#160;6 (15)&#160;</td><td rowspan="1" colspan="1">0.24*</td></tr><tr><td rowspan="1" colspan="1">Antidepressant, n (%)</td><td rowspan="1" colspan="1">&#160;18 (10)&#160;</td><td rowspan="1" colspan="1">&#160;12 (8)&#160;</td><td rowspan="1" colspan="1">&#160;6 (15)&#160;</td><td rowspan="1" colspan="1">0.24*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">MTX (mg/week), median (min-max)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;14)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;14)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;12)</td><td rowspan="1" colspan="1">0.57**</td></tr><tr><td rowspan="1" colspan="1">MTX (previous/current), n (%)</td><td rowspan="1" colspan="1">&#160;58 (31)&#160;</td><td rowspan="1" colspan="1">&#160;49 (34)&#160;</td><td rowspan="1" colspan="1">&#160;9 (22)&#160;</td><td rowspan="1" colspan="1">0.18*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">MTX duration (month), median (min-max)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;228)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;228)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;134)</td><td rowspan="1" colspan="1">0.13**</td></tr><tr><td rowspan="1" colspan="1">csDMARDs, n (%)</td><td rowspan="1" colspan="1">&#160;37 (20)&#160;</td><td rowspan="1" colspan="1">&#160;31 (21)&#160;</td><td rowspan="1" colspan="1">&#160;6 (15)&#160;</td><td rowspan="1" colspan="1">0.51*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">bDMARDs,&#160; n (%)</td><td rowspan="1" colspan="1">&#160;14 (8)&#160;</td><td rowspan="1" colspan="1">&#160;13 (9)&#160;</td><td rowspan="1" colspan="1">&#160;1 (2)&#160;</td><td rowspan="1" colspan="1">0.31*</td></tr><tr><td rowspan="1" colspan="1">bDMARDs (previous/current), n (%)</td><td rowspan="1" colspan="1">&#160;20 (11)&#160;</td><td rowspan="1" colspan="1">&#160;19 (13.0)&#160;</td><td rowspan="1" colspan="1">&#160;1 (2)&#160;</td><td rowspan="1" colspan="1">0.082*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">bDMARDs duration (month),&#160; median (min-max)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;240)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;240)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;13)</td><td rowspan="1" colspan="1">0.051**</td></tr><tr><td rowspan="1" colspan="1">PSL (mg), median (min-max)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;30)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;30)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;30)</td><td rowspan="1" colspan="1">0.15**</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">PSL (previous/current), n (%)</td><td rowspan="1" colspan="1">&#160;47 (25)&#160;</td><td rowspan="1" colspan="1">&#160;35 (24)&#160;</td><td rowspan="1" colspan="1">12 (29)&#160;</td><td rowspan="1" colspan="1">0.54*</td></tr><tr><td rowspan="1" colspan="1">PSL duration (months), median (min-max)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;468)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;468)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;264)</td><td rowspan="1" colspan="1">0.63**</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">NSAIDs, n (%)</td><td rowspan="1" colspan="1">&#160;81 (43)&#160;</td><td rowspan="1" colspan="1">&#160;62 (43)&#160;</td><td rowspan="1" colspan="1">19 (46)&#160;</td><td rowspan="1" colspan="1">0.72*</td></tr><tr><td rowspan="1" colspan="1">Pregabalin, n (%)</td><td rowspan="1" colspan="1">&#160;10 (5)&#160;</td><td rowspan="1" colspan="1">&#160; 6 (4)&#160;</td><td rowspan="1" colspan="1">&#160;4 (10)&#160;</td><td rowspan="1" colspan="1">0.23*</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">CRP (mg/dL), median (min-max)</td><td rowspan="1" colspan="1">&#160;0.12 (0&#8211;7.6)</td><td rowspan="1" colspan="1">&#160;0.14 (0&#8211;7.6)</td><td rowspan="1" colspan="1">&#160;0.09 (0&#8211;5.4)</td><td rowspan="1" colspan="1">0.46**</td></tr><tr><td rowspan="1" colspan="1">ESR (mm), median (min-max)</td><td rowspan="1" colspan="1">11 (2&#8211;124)</td><td rowspan="1" colspan="1">11 (2&#8211;124)</td><td rowspan="1" colspan="1">11 (2&#8211;53)</td><td rowspan="1" colspan="1">0.55**</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">ACPA (U/mL), median (min-max)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;1250)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;1250)</td><td rowspan="1" colspan="1">&#160;0 (0&#8211;394)</td><td rowspan="1" colspan="1">0.064**</td></tr><tr><td rowspan="1" colspan="1">RF (IU/mL), median (min-max)</td><td rowspan="1" colspan="1">13.1 (0&#8211;1050)</td><td rowspan="1" colspan="1">12.5 (0&#8211;1050)</td><td rowspan="1" colspan="1">16.1 (0&#8211;446.9)</td><td rowspan="1" colspan="1">0.95**</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">SS-A (U/mL), median (min-max)</td><td rowspan="1" colspan="1">&#160;0 (0-128)</td><td rowspan="1" colspan="1">&#160;0 (0-128)</td><td rowspan="1" colspan="1">&#160;0 (0-32)</td><td rowspan="1" colspan="1">0.43**</td></tr></tbody></table></table-wrap><p>In logistic regression analysis, only the NRS score was significantly associated with NeP (p&lt;0.001, odds ratio (OR)=1.37, 95% CI: 1.17-1.60); US inflammation showed no association with NeP (p=0.19, OR=0.80, 95% CI: 0.57-1.12) (Table <xref rid="TAB2" ref-type="table">2</xref>).</p><table-wrap position="float" id="TAB2" orientation="portrait"><label>Table 2</label><caption><title>Logistic regression associated with NeP </title><p>Logistic regression analysis was performed for items with significant differences in Table <xref rid="TAB1" ref-type="table">1</xref> and for US inflammation, after adjustment for age.</p><p>NeP: neuropathic pain; NRS: numerical rating scale score; US: ultrasound; SJC: swollen joint count; OR: odds ratio</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Variable</td><td rowspan="1" colspan="1">OR (95% CI)</td><td rowspan="1" colspan="1">P-value</td></tr><tr><td rowspan="1" colspan="1">NRS</td><td rowspan="1" colspan="1">1.37 (1.17&#8211;1.60)</td><td rowspan="1" colspan="1">&lt;0.001</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">US inflammation</td><td rowspan="1" colspan="1">0.80 (0.57&#8211;1.12)</td><td rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">Age&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td rowspan="1" colspan="1">1.01 (0.98&#8211;1.04)</td><td rowspan="1" colspan="1">0.50</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">SJC&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td rowspan="1" colspan="1">1.03 (0.98&#8211;1.08)</td><td rowspan="1" colspan="1">0.27</td></tr></tbody></table></table-wrap><p>Differences in PDQ components with and without US inflammation</p><p>The severity of burning pain was significantly higher in the M/H group than in the N/L group by the MWU test (p=0.032) (Table <xref rid="TAB3" ref-type="table">3</xref>) and in logistic analysis (p=0.01, OR=1.53, 95% CI: 1.1-2.1).</p><table-wrap position="float" id="TAB3" orientation="portrait"><label>Table 3</label><caption><title>PainDETECT questionnaire items: N/L group vs M/H group</title><p>N/L group: patients with no/low synovitis; M/H group: patients with moderate/high synovitis; VAS: visual analog scale; Mann&#8211;Whitney U test was used.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Variable</td><td rowspan="1" colspan="1">Overall</td><td rowspan="1" colspan="1">N/L group</td><td rowspan="1" colspan="1">M/H group</td><td rowspan="1" colspan="1">p-value</td></tr><tr><td rowspan="1" colspan="1">n</td><td rowspan="1" colspan="1">187</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">88</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Pain course pattern - n (%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">0.635</td></tr><tr><td rowspan="1" colspan="1">Persistent pain with slight fluctuations</td><td rowspan="1" colspan="1">83 (44)</td><td rowspan="1" colspan="1">43 (43)</td><td rowspan="1" colspan="1">40 (46)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Persistent pain with pain attacks</td><td rowspan="1" colspan="1">34 (18.2)</td><td rowspan="1" colspan="1">16 (16)</td><td rowspan="1" colspan="1">18 (21)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Pain attacks without intervening pain</td><td rowspan="1" colspan="1">48 (26)</td><td rowspan="1" colspan="1">29 (29)</td><td rowspan="1" colspan="1">19 (22)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Pain attacks with intervening pain</td><td rowspan="1" colspan="1">22 (12)</td><td rowspan="1" colspan="1">11 (11)</td><td rowspan="1" colspan="1">11 (13)</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Radiating pain - n (%)</td><td rowspan="1" colspan="1">31 (17)</td><td rowspan="1" colspan="1">15 (15)&#160;</td><td rowspan="1" colspan="1">16 (18)</td><td rowspan="1" colspan="1">0.694</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Pain quality- median (min-max)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Burning</td><td rowspan="1" colspan="1">0 (0&#8211;5)</td><td rowspan="1" colspan="1">0 (0&#8211;4)&#160;&#160;&#160;&#160;&#160;</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">0.032</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Tingling or prickling</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">1 (0&#8211;4)</td><td rowspan="1" colspan="1">0.723</td></tr><tr><td rowspan="1" colspan="1">Allodynia</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">1 (0&#8211;4)</td><td rowspan="1" colspan="1">0.749</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sudden pain attacks/electric shocks</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">1 (0&#8211;4)</td><td rowspan="1" colspan="1">0.588</td></tr><tr><td rowspan="1" colspan="1">Hypersensitivity to cold or heat</td><td rowspan="1" colspan="1">0 (0&#8211;5)</td><td rowspan="1" colspan="1">0 (0&#8211;5)</td><td rowspan="1" colspan="1">0 (0&#8211;3)</td><td rowspan="1" colspan="1">0.411</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Numbness</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">1 (0&#8211;5)</td><td rowspan="1" colspan="1">1 (0&#8211;4)</td><td rowspan="1" colspan="1">0.232</td></tr><tr><td rowspan="1" colspan="1">Hypersensitivity to pressure</td><td rowspan="1" colspan="1">2 (0&#8211;5)</td><td rowspan="1" colspan="1">2 (0&#8211;5)</td><td rowspan="1" colspan="1">2 (0&#8211;5)</td><td rowspan="1" colspan="1">0.541</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Pain VAS (cm) - median (min-max)</td><td rowspan="1" colspan="1">4 (0&#8211;10)</td><td rowspan="1" colspan="1">4 (0&#8211;9)</td><td rowspan="1" colspan="1">4 (0&#8211;10)</td><td rowspan="1" colspan="1">0.452</td></tr><tr><td rowspan="1" colspan="1">Mean (cm) - median (min-max)</td><td rowspan="1" colspan="1">5 (0&#8211;10)</td><td rowspan="1" colspan="1">5 (0&#8211;10)</td><td rowspan="1" colspan="1">5 (0&#8211;10)</td><td rowspan="1" colspan="1">0.56</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Strong (cm) - median (min-max)</td><td rowspan="1" colspan="1">7 (0&#8211;10)</td><td rowspan="1" colspan="1">7 (0&#8211;10)</td><td rowspan="1" colspan="1">6 (0&#8211;10)</td><td rowspan="1" colspan="1">0.724</td></tr></tbody></table></table-wrap><p>Association between US inflammation, NeP, and pain</p><p>Correlation Between Pain and PainDETECT With and Without US Inflammation</p><p>Although the overall analysis in Table <xref rid="TAB1" ref-type="table">1</xref> showed no significant association between NeP and US inflammation, we predicted an association between NRS, NeP, and US inflammation, so we performed a subgroup analysis by dividing into the N/L and M/H groups.</p><p>Correlations between NRS and NeP were observed in both the N/L (Spearman&#8217;s &#961;=0.516, p&lt;0.001; R&#178;=0.2717, p&lt;0.001) and M/H groups (Spearman&#8217;s &#961;=0.397, p&lt;0.001; R&#178;=0.1534, p&lt;0.001) in entire patients. However, in the analysis of only RA patients, NRS was significantly correlated with NeP only in the M/H group (Spearman&#8217;s &#961;=0.431, p=0.002; R&#178;=0.212, p&lt;0.001) but not in the N/L group (Spearman&#8217;s &#961;=0.251, p=0.3; R&#178;=0.03849, p=0.4208).</p><p>In the RA group, a comparison using simple regression analysis between the N/L group and the M/H group showed that ESR (p=0.001), CRP (p=0.002), ACPA (p=0.004), duration of bDMARDs (p=0.013), history of bDMARDs&#160;(p=0.03), RF (p=0.037), and antidepressant use (p=0.04) were higher in the M/H group (Table <xref rid="TAB4" ref-type="table">4</xref>).&#160;There was no significant difference in NRS and&#160;PDQ scores.</p><table-wrap position="float" id="TAB4" orientation="portrait"><label>Table 4</label><caption><title>Characteristics of patients with N/L and M/H in the RA group</title><p>RA: rheumatoid arthritis; N/L group:&#160;no/low US inflammation; M/H group:&#160;&#160;moderate/high US inflammation; PGA: patient global assessment; TJC: tender joint count; SJC: swollen joint count; HAQ: health assessment questionnaire; US: ultrasonography; MTX: methotrexate; DMARD: Disease modifying anti rheumatic drug; PSL: prednisolone; NSAIDs: non-steroidal anti-inflammatory drugs; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; ACPA: anti-cyclic citrullinated peptide antibody; RF: rheumatoid factor</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Variable</td><td rowspan="1" colspan="1">N/Lgroup</td><td rowspan="1" colspan="1">M/Hgroup</td><td rowspan="1" colspan="1">p-value</td></tr><tr><td rowspan="1" colspan="1">n</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Age (years) &#8211; median (min-max)</td><td rowspan="1" colspan="1">52 (22-77)</td><td rowspan="1" colspan="1">57 (18-83)</td><td rowspan="1" colspan="1">0.26</td></tr><tr><td rowspan="1" colspan="1">Female sex, n (%)</td><td rowspan="1" colspan="1">15 (78.9)&#160;</td><td rowspan="1" colspan="1">44 (86.3)&#160;</td><td rowspan="1" colspan="1">0.47</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Symptoms duration (years), median (min-max)</td><td rowspan="1" colspan="1">4 (1-22)</td><td rowspan="1" colspan="1">6 (0-33)</td><td rowspan="1" colspan="1">0.84</td></tr><tr><td rowspan="1" colspan="1">NRS score, median (min-max)</td><td rowspan="1" colspan="1">4(1-9)</td><td rowspan="1" colspan="1">4 (0-9)</td><td rowspan="1" colspan="1">0.34</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Average, median (min-max)</td><td rowspan="1" colspan="1">5 (2-9)</td><td rowspan="1" colspan="1">5 (0-10)</td><td rowspan="1" colspan="1">0.62</td></tr><tr><td rowspan="1" colspan="1">Greatest, median (min-max)</td><td rowspan="1" colspan="1">7 (2-10)</td><td rowspan="1" colspan="1">6 (0-10)</td><td rowspan="1" colspan="1">0.53</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">PainDETECT, median (min-max)</td><td rowspan="1" colspan="1">8 (2-14)</td><td rowspan="1" colspan="1">6 (0-19)</td><td rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1">PGA, median (min-max)</td><td rowspan="1" colspan="1">4 (1-10)</td><td rowspan="1" colspan="1">5 (0-9)</td><td rowspan="1" colspan="1">0.86</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">TJC53, median (min-max)</td><td rowspan="1" colspan="1">11 (0-53)</td><td rowspan="1" colspan="1">5 (0-32)</td><td rowspan="1" colspan="1">0.14</td></tr><tr><td rowspan="1" colspan="1">SJC, median (min-max)</td><td rowspan="1" colspan="1">1 (0-17)</td><td rowspan="1" colspan="1">2 (0-20)</td><td rowspan="1" colspan="1">0.39</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">HAQ, median (min-max)</td><td rowspan="1" colspan="1">0.12 (0-1.88)</td><td rowspan="1" colspan="1">0.38 (0-2.25)</td><td rowspan="1" colspan="1">0.14</td></tr><tr><td rowspan="1" colspan="1">X-ray Steinblocker grade, n (%)</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">9 (47.4)&#160;</td><td rowspan="1" colspan="1">19 (37.3)&#160;</td><td rowspan="1" colspan="1">0.59</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">4 (21.1)&#160;</td><td rowspan="1" colspan="1">19 (37.3)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">4 (21.1)&#160;</td><td rowspan="1" colspan="1">8 (15.7)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2 (10.5)&#160;</td><td rowspan="1" colspan="1">5 (9.8)&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Mental disorder, n (%)</td><td rowspan="1" colspan="1">2 ( 10.5)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0.07</td></tr><tr><td rowspan="1" colspan="1">Antidepressant, n (%)</td><td rowspan="1" colspan="1">4 (21.1)&#160;</td><td rowspan="1" colspan="1">2 (3.9)&#160;</td><td rowspan="1" colspan="1">0.04</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">MTX (mg/week), median (min-max)</td><td rowspan="1" colspan="1">0 (0-12)</td><td rowspan="1" colspan="1">0 (0-12)</td><td rowspan="1" colspan="1">0.78</td></tr><tr><td rowspan="1" colspan="1">MTX (previous/current), n (%)</td><td rowspan="1" colspan="1">12 (63.2)&#160;</td><td rowspan="1" colspan="1">29 (56.9)&#160;</td><td rowspan="1" colspan="1">0.79</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">MTX duration (month), median (min-max)</td><td rowspan="1" colspan="1">4 (0-228)</td><td rowspan="1" colspan="1">4 (0-160)</td><td rowspan="1" colspan="1">0.84</td></tr><tr><td rowspan="1" colspan="1">csDMARDs, n (%)</td><td rowspan="1" colspan="1">11 (57.9)&#160;</td><td rowspan="1" colspan="1">11 (37.3)&#160;</td><td rowspan="1" colspan="1">0.18</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">bDMARDs, n (%)</td><td rowspan="1" colspan="1">6 (31.6)&#160;</td><td rowspan="1" colspan="1">5 (9.8)&#160;</td><td rowspan="1" colspan="1">0.06</td></tr><tr><td rowspan="1" colspan="1">bDMARDs (previous/current), n (%)</td><td rowspan="1" colspan="1">7 (36.8)&#160;</td><td rowspan="1" colspan="1">6 (11.8)&#160;</td><td rowspan="1" colspan="1">0.03</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">bDMARDs duration (month), median (min-max)</td><td rowspan="1" colspan="1">0 (0-240)</td><td rowspan="1" colspan="1">0 (0-12)</td><td rowspan="1" colspan="1">0.013</td></tr><tr><td rowspan="1" colspan="1">PSLmg</td><td rowspan="1" colspan="1">0 (0-5)</td><td rowspan="1" colspan="1">0 (0-10)</td><td rowspan="1" colspan="1">0.63</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">PSL (previous/current), n (%)</td><td rowspan="1" colspan="1">7 (36.8)&#160;</td><td rowspan="1" colspan="1">18 (35.3)&#160;</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">PSL duration (months), median (min-max)</td><td rowspan="1" colspan="1">0 (0-92)</td><td rowspan="1" colspan="1">0 (0-468)</td><td rowspan="1" colspan="1">0.78</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">NSAIDs, n (%)</td><td rowspan="1" colspan="1">9 (47.4)&#160;</td><td rowspan="1" colspan="1">24 (47.1)&#160;</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Pregabalin, n (%)</td><td rowspan="1" colspan="1">2 (10.5)&#160;</td><td rowspan="1" colspan="1">0 (0)&#160;</td><td rowspan="1" colspan="1">0.07</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">CRP (mg/dL), median (min-max)</td><td rowspan="1" colspan="1">0.04 (0-0.56)</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">ESR (mm), median (min-max)</td><td rowspan="1" colspan="1">7 (2-41)</td><td rowspan="1" colspan="1">17 (2-91)</td><td rowspan="1" colspan="1">0.001</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">ACPA (U/mL), median (min-max)</td><td rowspan="1" colspan="1">0 (0-300)</td><td rowspan="1" colspan="1">73.1 (0-1250)</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">RF (IU/mL), median (min-max)</td><td rowspan="1" colspan="1">11.4 (0-143.8)</td><td rowspan="1" colspan="1">33.7 (0-446.9)</td><td rowspan="1" colspan="1">0.037</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">SS-A (U/mL), median (min-max)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0-32)</td><td rowspan="1" colspan="1">0.03</td></tr></tbody></table></table-wrap><p>ROC Curve</p><p>To investigate the contribution of NeP to NRS in the presence or absence of US inflammation in the RA group, ROC curve analysis was used to determine the NRS cut-off that determined the presence of NeP. In the N/L group, the optimal cut-off was four (50% sensitivity and 66.7% specificity, area under the curve (AUC)=0.521, 95% CI 0.132-0.91), while in the M/H group, the optimal cut-off was six (76.2% sensitivity and 66.7% specificity, AUC=0.757, 95% CI 0.601-0.912) (Figure <xref rid="FIG2" ref-type="fig">2</xref>).&#160;The ROC curve for the N/L group had a lower AUC (0.521) than the M/H group (0.757), and was less reliable.</p><fig position="anchor" fig-type="figure" id="FIG2" orientation="portrait"><label>Figure 2</label><caption><title> The optimal NRS cut-off score for diagnosing NeP in the RA group</title><p>In the RA group, the ROC curve analysis was performed to determine the NRS cut-off for diagnosing NeP in both&#160;N/L and M/H groups.</p><p>(a) N/L group. Cut-off: 4, 50% sensitivity and 66.7% specificity, AUC=0.521, 95% CI 0.132-0.91; (b) M/H group. Cut-off: 6, 76.2% sensitivity and 66.7% specificity, AUC=0.757, 95% CI&#160;0.601-0.912.</p><p>ROC: receiver operating characteristic; NRS: numeric rating scale; RA: rheumatoid arthritis; N/L group: patients with no/low synovitis; M/H group: patients with moderate/high synovitis; US: ultrasound; AUC: area under the curve</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091169-i02.jpg"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, we conducted a multi-faceted analysis of refractory pain of unknown origin using the PDQ to assess non-inflammatory pain and MSKUS&#160;to assess the presence or absence of inflammation. The results showed that pain intensity was significantly associated with non-inflammatory pain, but there was no association with inflammatory findings detected by MSKUS. It was also found that non-inflammatory pain could not be predicted from patient background factors and that only pain intensity was a useful associated factor. In addition, it was suggested that inflammatory findings detected by MSKUS were related to pain quality as burning pain, and may have a greater impact on pain quality than pain intensity. These results clearly distinguish the effects of inflammatory and non-inflammatory factors in refractory pain and suggest the need for more personalized pain management.</p><p>In patients with unexplained chronic joint pain, non-inflammatory factors such as NeP and PGA were more associated with pain than inflammatory factors. NeP was significantly associated with pain, as previously reported [<xref rid="REF4" ref-type="bibr">4</xref>, <xref rid="REF11" ref-type="bibr">11</xref>, <xref rid="REF15" ref-type="bibr">15</xref>]. Pain should not be underestimated, even in the absence of US inflammation. A previous study showed a discrepancy between PGA&#160;and Evaluator Global Assessment (EGA); specifically, the main determinant of PGA was pain, and the determinant of EGA was SJC [<xref rid="REF27" ref-type="bibr">27</xref>]. This suggests that physicians were not focusing enough on pain, and this issue should be addressed in relation to NeP.</p><p>The quality of pain in this trial varied according to the presence or absence of US inflammation. Burning pain was more severe in patients with US inflammation. Burning pain was the most common NeP symptom and was also common in patients with RA [<xref rid="REF28" ref-type="bibr">28</xref>]. It was associated with damage to the nociceptive system [<xref rid="REF29" ref-type="bibr">29</xref>]. In a review of post-herpetic neuralgia, burning pain was common in herpes zoster infection due to sensitization of cutaneous nociceptor endings (irritable nociceptors) by the herpes rash and inflammation [<xref rid="REF30" ref-type="bibr">30</xref>]. The finding that burning pain was more severe in patients with MSKUS inflammation suggests the presence of peripheral sensitization due to inflammation. Thus, even in patients with high PDQ scores, the mechanism of pain may differ depending on the presence or absence of US inflammation: a high PDQ score in patients with US inflammation may indicate peripheral sensitization induced by inflammation, whereas a high PDQ score in patients without US inflammation may be due to true NeP without inflammation. The combined use of US and PDQ may accurately identify NeP. Therefore, if the US is negative for inflammation, analgesic therapy should be considered rather than increasing DMARDs.</p><p>In the RA group, the presence or absence of US inflammation was associated only with inflammatory factors such as CRP and RF, and&#160;there was no association with pain intensity or the presence or absence of NeP, as previously. However, the significant correlation between NRS and NeP was observed both with and without US inflammation in all patients, but in RA patients, the correlation was only observed in the group of RA patients with US inflammation. When RA patients have inflammation, the symptoms may be NeP-like due to the quality of pain, with burning pain. Inflammation may change the quality of pain rather than the intensity of pain. When using the PDQ in RA patients, it may be necessary to be aware that burning pain increases in the group of patients with high MSKUS inflammation, which may lead to more patients being considered NeP. The cause of pain in RA without inflammation may be complex and not only explained by NeP.</p><p>Patients without MSKUS inflammation but with a high NRS should be treated for potential NeP, whereas patients with MSKUS inflammation may have peripheral nociceptor sensitization due to inflammation and may benefit from anti-inflammatory drug treatment. This is consistent with the algorithm of the EULAR recommendation [<xref rid="REF21" ref-type="bibr">21</xref>] that MSKUS should be performed for D2TRA and that anti-inflammatory drug therapy should be considered if US inflammation is present, whereas non-pharmacological therapy (education, exercise, self-management) is preferable to increasing the dose of DMARDs if US inflammation is absent.</p><p>There are several limitations to this study. Because the participants included not only people with RA but also people with undiagnosed joint pain and other rheumatic diseases, not all of the results may be applicable to RA. In addition, because MSKUS is indicated when the diagnosis or cause of joint pain is unknown, patients who undergo MSKUS are more likely to complain of pain, which introduces a selection bias. Also, although mental illness was not associated with NeP in this study, the results may have been different if current mental status had been assessed using the SF36 or other methods, as the study analyses were based on medical record data only. Recently, NeP in RA has been reported to be part of a central sensitization syndrome [<xref rid="REF31" ref-type="bibr">31</xref>], and the Central Sensitization Inventory (CSI) has also been used as a questionnaire. Future surveys using the CSI are being considered.</p><p>A strength of this study is the combined use of the PDQ to evaluate non-inflammatory pain and MSKUS to objectively detect inflammatory changes. This enabled a clear distinction between inflammatory and non-inflammatory components of refractory joint pain and how pain intensity and quality are influenced by inflammation.&#160;While EULAR recommendations have noted the importance of the presence or absence of US inflammation in the treatment of refractory RA, this study introduces a novel finding by identifying that the quality of pain may differ depending on the presence or absence of US inflammation. This finding further supports the recommendations.&#160;Clinically, these findings may contribute to more personalized and effective management of refractory joint pain.&#160;</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>We conducted an observational, cross-sectional study of patients with unexplained arthralgia, using US and PDQ. The results showed that inflammatory findings detected by MSKUS were related to quality of pain, such as burning pain, and may have a greater impact on pain quality than pain intensity. It may contribute to more personalized and effective management of refractory joint pain.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Informed consent for treatment and open access publication was obtained or waived by all participants in this study. The ethics committee at Juntendo University issued approval (H21-0021).</p><p><bold>Animal subjects:</bold> All authors have confirmed that this study did not involve animal subjects or tissue.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#160; Mariko Harada, Michihiro Ogasawara</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#160; Mariko Harada, Michihiro Ogasawara, Shuko Nojiri, Yuko Matsuki-Muramoto, Toshio Kawamoto, Ken Yamaji, Naoto Tamura</p><p><bold>Drafting of the manuscript:</bold>&#160; Mariko Harada</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#160; Mariko Harada, Michihiro Ogasawara, Shuko Nojiri, Yuko Matsuki-Muramoto, Toshio Kawamoto, Ken Yamaji, Naoto Tamura</p><p><bold>Supervision:</bold>&#160; Michihiro Ogasawara, Ken Yamaji, Naoto Tamura</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Management of rheumatoid arthritis: the 2012 perspective</article-title><source>Mod Rheumatol</source><person-group><name name-style="western"><surname>Yamanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Seto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>E</given-names></name><etal/></person-group><fpage>1</fpage><lpage>7</lpage><volume>23</volume><year>2013</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3109/s10165-012-0702-1">https://doi.org/10.3109/s10165-012-0702-1</uri><pub-id pub-id-type="pmid">22772460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10165-012-0702-1</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Systematic literature review of residual symptoms and an unmet need in patients with rheumatoid arthritis</article-title><source>Arthritis Care Res (Hoboken)</source><person-group><name name-style="western"><surname>Michaud</surname><given-names>K</given-names></name><name name-style="western"><surname>Pope</surname><given-names>J</given-names></name><name name-style="western"><surname>van de Laar</surname><given-names>M</given-names></name><etal/></person-group><fpage>1606</fpage><lpage>1616</lpage><volume>73</volume><year>2021</year><pub-id pub-id-type="pmid">32619340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.24369</pub-id><pub-id pub-id-type="pmcid">PMC8596735</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Pain in rheumatoid arthritis</article-title><source>Curr Pain Headache Rep</source><person-group><name name-style="western"><surname>Walsh</surname><given-names>DA</given-names></name><name name-style="western"><surname>McWilliams</surname><given-names>DF</given-names></name></person-group><fpage>509</fpage><lpage>517</lpage><volume>16</volume><year>2012</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1007/s11916-012-0303-x">https://doi.org/10.1007/s11916-012-0303-x</uri><pub-id pub-id-type="pmid">23109051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11916-012-0303-x</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Determinants of non-nociceptive pain in rheumatoid arthritis</article-title><source>Acta Reumatol Port</source><person-group><name name-style="western"><surname>Martins Rocha</surname><given-names>T</given-names></name><name name-style="western"><surname>Pimenta</surname><given-names>S</given-names></name><name name-style="western"><surname>Bernardo</surname><given-names>A</given-names></name><etal/></person-group><fpage>291</fpage><lpage>303</lpage><volume>43</volume><year>2018</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/30641538/">https://pubmed.ncbi.nlm.nih.gov/30641538/</uri><pub-id pub-id-type="pmid">30641538</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis</article-title><source>Nat Rev Rheumatol</source><person-group><name name-style="western"><surname>Buch</surname><given-names>MH</given-names></name><name name-style="western"><surname>Eyre</surname><given-names>S</given-names></name><name name-style="western"><surname>McGonagle</surname><given-names>D</given-names></name></person-group><fpage>17</fpage><lpage>33</lpage><volume>17</volume><year>2021</year><pub-id pub-id-type="pmid">33293696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41584-020-00541-7</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Prevalence of migraine and neuropathic pain in rheumatic diseases</article-title><source>J Clin Med</source><person-group><name name-style="western"><surname>Mathieu</surname><given-names>S</given-names></name><name name-style="western"><surname>Couderc</surname><given-names>M</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>B</given-names></name><etal/></person-group><fpage>1715</fpage><volume>9</volume><year>2020</year><pub-id pub-id-type="pmid">32560321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm9061890</pub-id><pub-id pub-id-type="pmcid">PMC7356241</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>How do neuropathic pain-like symptoms affect health-related quality of life among patients with rheumatoid arthritis? A comparison of multiple pain-related parameters</article-title><source>Mod Rheumatol</source><person-group><name name-style="western"><surname>Noda</surname><given-names>K</given-names></name><name name-style="western"><surname>Tajima</surname><given-names>M</given-names></name><name name-style="western"><surname>Oto</surname><given-names>Y</given-names></name><etal/></person-group><fpage>828</fpage><lpage>834</lpage><volume>30</volume><year>2020</year><pub-id pub-id-type="pmid">31398076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14397595.2019.1650462</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Pain mechanisms in rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><person-group><name name-style="western"><surname>McWilliams</surname><given-names>DF</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>DA</given-names></name></person-group><fpage>94</fpage><lpage>101</lpage><volume>35 Suppl 107</volume><year>2017</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28967354/">https://pubmed.ncbi.nlm.nih.gov/28967354/</uri><pub-id pub-id-type="pmid">28967354</pub-id></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Non-nociceptive pain in rheumatoid arthritis is frequent and affects disease activity estimation: cross-sectional data from the FRAME study</article-title><source>Scand J Rheumatol</source><person-group><name name-style="western"><surname>Christensen</surname><given-names>AW</given-names></name><name name-style="western"><surname>Rifbjerg-Madsen</surname><given-names>S</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>R</given-names></name><etal/></person-group><fpage>461</fpage><lpage>469</lpage><volume>45</volume><year>2016</year><pub-id pub-id-type="pmid">26987470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/03009742.2016.1139174</pub-id></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis</article-title><source>Arthritis Res Ther</source><person-group><name name-style="western"><surname>Koop</surname><given-names>SM</given-names></name><name name-style="western"><surname>ten Klooster</surname><given-names>PM</given-names></name><name name-style="western"><surname>Vonkeman</surname><given-names>HE</given-names></name><name name-style="western"><surname>Steunebrink</surname><given-names>LM</given-names></name><name name-style="western"><surname>van de Laar</surname><given-names>MA</given-names></name></person-group><fpage>237</fpage><volume>17</volume><year>2015</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1186/s13075-015-0761-8">https://doi.org/10.1186/s13075-015-0761-8</uri><pub-id pub-id-type="pmid">26335941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-015-0761-8</pub-id><pub-id pub-id-type="pmcid">PMC4558794</pub-id></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting</article-title><source>J Pain Res</source><person-group><name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name><name name-style="western"><surname>Magan</surname><given-names>T</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>M</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>A</given-names></name><name name-style="western"><surname>Sofat</surname><given-names>N</given-names></name></person-group><fpage>579</fpage><lpage>588</lpage><volume>7</volume><year>2014</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.2147/JPR.S69011">https://doi.org/10.2147/JPR.S69011</uri><pub-id pub-id-type="pmid">25378947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JPR.S69011</pub-id><pub-id pub-id-type="pmcid">PMC4207578</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>An analysis of the neuropathic pain components in rheumatoid arthritis patients</article-title><source>Intern Med</source><person-group><name name-style="western"><surname>Ito</surname><given-names>S</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>D</given-names></name><name name-style="western"><surname>Murasawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Narita</surname><given-names>I</given-names></name><name name-style="western"><surname>Nakazono</surname><given-names>K</given-names></name></person-group><fpage>479</fpage><lpage>485</lpage><volume>57</volume><year>2018</year><pub-id pub-id-type="pmid">29225253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2169/internalmedicine.9235-17</pub-id><pub-id pub-id-type="pmcid">PMC5849541</pub-id></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>A new definition of neuropathic pain</article-title><source>Pain</source><person-group><name name-style="western"><surname>Jensen</surname><given-names>TS</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R</given-names></name><name name-style="western"><surname>Haanp&#228;&#228;</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalso</surname><given-names>E</given-names></name><name name-style="western"><surname>Loeser</surname><given-names>JD</given-names></name><name name-style="western"><surname>Rice</surname><given-names>AS</given-names></name><name name-style="western"><surname>Treede</surname><given-names>RD</given-names></name></person-group><fpage>2204</fpage><lpage>2205</lpage><volume>152</volume><year>2011</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1016/j.pain.2011.06.017">https://doi.org/10.1016/j.pain.2011.06.017</uri><pub-id pub-id-type="pmid">21764514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2011.06.017</pub-id></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Mechanisms, impact and management of pain in rheumatoid arthritis</article-title><source>Nat Rev Rheumatol</source><person-group><name name-style="western"><surname>Walsh</surname><given-names>DA</given-names></name><name name-style="western"><surname>McWilliams</surname><given-names>DF</given-names></name></person-group><fpage>581</fpage><lpage>592</lpage><volume>10</volume><year>2014</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1038/nrrheum.2014.64">https://doi.org/10.1038/nrrheum.2014.64</uri><pub-id pub-id-type="pmid">24861185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrrheum.2014.64</pub-id></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Comparison of pain, pain burden, coping strategies, and attitudes between patients with systemic sclerosis and patients with rheumatoid arthritis: a cross-sectional study</article-title><source>Pain Med</source><person-group><name name-style="western"><surname>Perrot</surname><given-names>S</given-names></name><name name-style="western"><surname>Dieud&#233;</surname><given-names>P</given-names></name><name name-style="western"><surname>P&#233;rocheau</surname><given-names>D</given-names></name><name name-style="western"><surname>Allanore</surname><given-names>Y</given-names></name></person-group><fpage>1776</fpage><lpage>1785</lpage><volume>14</volume><year>2013</year><pub-id pub-id-type="pmid">23899271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pme.12213</pub-id></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Pain sensitization and neuropathic pain-like symptoms associated with effectiveness of exercise therapy in patients with hip and knee osteoarthritis</article-title><source>Pain Res Manag</source><person-group><name name-style="western"><surname>Hattori</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimo</surname><given-names>K</given-names></name><name name-style="western"><surname>Niwa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Katsura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tokiwa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohga</surname><given-names>S</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>T</given-names></name></person-group><fpage>4323045</fpage><volume>2022</volume><year>2022</year><pub-id pub-id-type="pmid">36071945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/4323045</pub-id><pub-id pub-id-type="pmcid">PMC9444422</pub-id></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain</article-title><source>Curr Med Res Opin</source><person-group><name name-style="western"><surname>Freynhagen</surname><given-names>R</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R</given-names></name><name name-style="western"><surname>Gockel</surname><given-names>U</given-names></name><name name-style="western"><surname>T&#246;lle</surname><given-names>TR</given-names></name></person-group><fpage>1911</fpage><lpage>1920</lpage><volume>22</volume><year>2006</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1185/030079906X132488.">http://doi.org/10.1185/030079906X132488.</uri><pub-id pub-id-type="pmid">17022849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1185/030079906X132488</pub-id></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Neuropathic pain in systemic sclerosis patients: a cross-sectional study</article-title><source>Reumatol Clin (Engl Ed)</source><person-group><name name-style="western"><surname>Sousa-Neves</surname><given-names>J</given-names></name><name name-style="western"><surname>Cerqueira</surname><given-names>M</given-names></name><name name-style="western"><surname>Santos-Faria</surname><given-names>D</given-names></name><name name-style="western"><surname>Afonso</surname><given-names>C</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>F</given-names></name></person-group><fpage>0</fpage><volume>15</volume><year>2019</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1016/j.reuma.2017.12.010">https://doi.org/10.1016/j.reuma.2017.12.010</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.reuma.2017.12.010</pub-id><pub-id pub-id-type="pmid">29397326</pub-id></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis</article-title><source>Rheumatology (Oxford)</source><person-group><name name-style="western"><surname>Nguyen</surname><given-names>H</given-names></name><name name-style="western"><surname>Ruyssen-Witrand</surname><given-names>A</given-names></name><name name-style="western"><surname>Gandjbakhch</surname><given-names>F</given-names></name><name name-style="western"><surname>Constantin</surname><given-names>A</given-names></name><name name-style="western"><surname>Foltz</surname><given-names>V</given-names></name><name name-style="western"><surname>Cantagrel</surname><given-names>A</given-names></name></person-group><fpage>2110</fpage><lpage>2118</lpage><volume>53</volume><year>2014</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1093/rheumatology/keu217">https://doi.org/10.1093/rheumatology/keu217</uri><pub-id pub-id-type="pmid">24929634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keu217</pub-id></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>Absence of ultrasound inflammation in patients presenting with arthralgia rules out the development of arthritis</article-title><source>Arthritis Res Ther</source><person-group><name name-style="western"><surname>van der Ven</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Veer-Meerkerk</surname><given-names>M</given-names></name><name name-style="western"><surname>Ten Cate</surname><given-names>DF</given-names></name><etal/></person-group><fpage>202</fpage><volume>19</volume><year>2017</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1186/s13075-017-1405-y">https://doi.org/10.1186/s13075-017-1405-y</uri><pub-id pub-id-type="pmid">28915847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-017-1405-y</pub-id><pub-id pub-id-type="pmcid">PMC5602837</pub-id></element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><person-group><name name-style="western"><surname>Nagy</surname><given-names>G</given-names></name><name name-style="western"><surname>Roodenrijs</surname><given-names>NM</given-names></name><name name-style="western"><surname>Welsing</surname><given-names>PM</given-names></name><etal/></person-group><fpage>20</fpage><lpage>33</lpage><volume>81</volume><year>2022</year><pub-id pub-id-type="pmid">34407926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2021-220973</pub-id><pub-id pub-id-type="pmcid">PMC8761998</pub-id></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>Validity and reliability of the Japanese version of the painDETECT questionnaire: a multicenter observational study</article-title><source>PLoS One</source><person-group><name name-style="western"><surname>Matsubayashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>K</given-names></name><name name-style="western"><surname>Sumitani</surname><given-names>M</given-names></name><etal/></person-group><fpage>0</fpage><volume>8</volume><year>2013</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0068013</pub-id><pub-id pub-id-type="pmcid">PMC3787034</pub-id><pub-id pub-id-type="pmid">24098629</pub-id></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>The painDETECT project - far more than a screening tool on neuropathic pain</article-title><source>Curr Med Res Opin</source><person-group><name name-style="western"><surname>Freynhagen</surname><given-names>R</given-names></name><name name-style="western"><surname>T&#246;lle</surname><given-names>TR</given-names></name><name name-style="western"><surname>Gockel</surname><given-names>U</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R</given-names></name></person-group><fpage>1033</fpage><lpage>1057</lpage><volume>32</volume><year>2016</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1185/03007995.2016.1157460">https://doi.org/10.1185/03007995.2016.1157460</uri><pub-id pub-id-type="pmid">26907456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1185/03007995.2016.1157460</pub-id></element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Examination of intra and interrater reliability with a new ultrasonographic reference atlas for scoring of synovitis in patients with rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><person-group><name name-style="western"><surname>Hammer</surname><given-names>HB</given-names></name><name name-style="western"><surname>Bolton-King</surname><given-names>P</given-names></name><name name-style="western"><surname>Bakkeheim</surname><given-names>V</given-names></name><name name-style="western"><surname>Berg</surname><given-names>TH</given-names></name><name name-style="western"><surname>Sundt</surname><given-names>E</given-names></name><name name-style="western"><surname>Kongtorp</surname><given-names>AK</given-names></name><name name-style="western"><surname>Haavardsholm</surname><given-names>EA</given-names></name></person-group><fpage>1995</fpage><lpage>1998</lpage><volume>70</volume><year>2011</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1136/ard.2011.152926">https://doi.org/10.1136/ard.2011.152926</uri><pub-id pub-id-type="pmid">21784724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard.2011.152926</pub-id></element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Missing data in clinical research: a tutorial on multiple imputation</article-title><source>Can J Cardiol</source><person-group><name name-style="western"><surname>Austin</surname><given-names>PC</given-names></name><name name-style="western"><surname>White</surname><given-names>IR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DS</given-names></name><name name-style="western"><surname>van Buuren</surname><given-names>S</given-names></name></person-group><fpage>1322</fpage><lpage>1331</lpage><volume>37</volume><year>2021</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1016/j.cjca.2020.11.010">https://doi.org/10.1016/j.cjca.2020.11.010</uri><pub-id pub-id-type="pmid">33276049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cjca.2020.11.010</pub-id><pub-id pub-id-type="pmcid">PMC8499698</pub-id></element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Investigation of the freely available easy-to-use software 'EZR' for medical statistics</article-title><source>Bone Marrow Transplant</source><person-group><name name-style="western"><surname>Kanda</surname><given-names>Y</given-names></name></person-group><fpage>452</fpage><lpage>458</lpage><volume>48</volume><year>2013</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1038/bmt.2012.244">https://doi.org/10.1038/bmt.2012.244</uri><pub-id pub-id-type="pmid">23208313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bmt.2012.244</pub-id><pub-id pub-id-type="pmcid">PMC3590441</pub-id></element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity</article-title><source>Arthritis Rheum</source><person-group><name name-style="western"><surname>Studenic</surname><given-names>P</given-names></name><name name-style="western"><surname>Radner</surname><given-names>H</given-names></name><name name-style="western"><surname>Smolen</surname><given-names>JS</given-names></name><name name-style="western"><surname>Aletaha</surname><given-names>D</given-names></name></person-group><fpage>2814</fpage><lpage>2823</lpage><volume>64</volume><year>2012</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1002/art.34543">https://doi.org/10.1002/art.34543</uri><pub-id pub-id-type="pmid">22810704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.34543</pub-id></element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Ultrasound-defined remission for good functional status in rheumatoid arthritis</article-title><source>Indian J Med Res</source><person-group><name name-style="western"><surname>Ozer</surname><given-names>PK</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>O</given-names></name><name name-style="western"><surname>Ozer</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cengiz</surname><given-names>AK</given-names></name><name name-style="western"><surname>Durmaz</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kaptanoglu</surname><given-names>E</given-names></name></person-group><fpage>230</fpage><lpage>236</lpage><volume>146</volume><year>2017</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.4103/ijmr.IJMR_548_15">https://doi.org/10.4103/ijmr.IJMR_548_15</uri><pub-id pub-id-type="pmid">29265024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmr.IJMR_548_15</pub-id><pub-id pub-id-type="pmcid">PMC5761033</pub-id></element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study</article-title><source>BMC Rheumatol</source><person-group><name name-style="western"><surname>Nawata</surname><given-names>M</given-names></name><name name-style="western"><surname>Someya</surname><given-names>K</given-names></name><name name-style="western"><surname>Funada</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nagayasu</surname><given-names>A</given-names></name><name name-style="western"><surname>Saito</surname><given-names>K</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y</given-names></name></person-group><fpage>49</fpage><volume>5</volume><year>2021</year><pub-id pub-id-type="pmid">34802464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41927-021-00221-3</pub-id><pub-id pub-id-type="pmcid">PMC8607696</pub-id></element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms</article-title><source>Nat Rev Neurol</source><person-group><name name-style="western"><surname>Truini</surname><given-names>A</given-names></name><name name-style="western"><surname>Garcia-Larrea</surname><given-names>L</given-names></name><name name-style="western"><surname>Cruccu</surname><given-names>G</given-names></name></person-group><fpage>572</fpage><lpage>582</lpage><volume>9</volume><year>2013</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1038/nrneurol.2013.180">https://doi.org/10.1038/nrneurol.2013.180</uri><pub-id pub-id-type="pmid">24018479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2013.180</pub-id></element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="journal"><article-title>Central sensitisation features are associated with neuropathic pain-like symptoms in patients with longstanding rheumatoid arthritis: a cross-sectional study using the central sensitisation inventory</article-title><source>Clin Exp Rheumatol</source><person-group><name name-style="western"><surname>Saitou</surname><given-names>M</given-names></name><name name-style="western"><surname>Noda</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsushita</surname><given-names>T</given-names></name><name name-style="western"><surname>Ukichi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kurosaka</surname><given-names>D</given-names></name></person-group><fpage>980</fpage><lpage>987</lpage><volume>40</volume><year>2022</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.55563/clinexprheumatol/msy022">https://doi.org/10.55563/clinexprheumatol/msy022</uri><pub-id pub-id-type="pmid">34128802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.55563/clinexprheumatol/msy022</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>